Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 32 Records) |
| Query Trace: Death and MUT[original query] |
|---|
| BRAF mutations in advanced cancers: clinical characteristics and outcomes. PloS one 2011 6 (10): e25806. El-Osta Hazem, Falchook Gerald, Tsimberidou Apostolia, Hong David, Naing Aung, Kim Kevin, Wen Sijin, Janku Filip, Kurzrock Razel |
| FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatric blood & cancer 2012 Oct 59 (4): 662-7. Kutny Matthew A, Moser Barry K, Laumann Kristina, Feusner James H, Gamis Alan, Gregory John, Larson Richard A, Powell Bayard L, Stock Wendy, Willman Cheryl L, Woods William G, Meshinchi Sohe |
| Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. The Lancet. Oncology 2015 Jun 16 (6): 686-94. Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu, Kristeleit Rebec |
| Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases. Journal of the National Cancer Institute 2016 Nov 108 (11): . Helgadottir Hildur, Höiom Veronica, Tuominen Rainer, Nielsen Kari, Jönsson Göran, Olsson Håkan, Hansson Joh |
| CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology 2016 5 (12): e1254313. D'Alterio Crescenzo, Nasti Guglielmo, Polimeno Marianeve, Ottaiano Alessandro, Conson Manuel, Circelli Luisa, Botti Giovanni, Scognamiglio Giosuè, Santagata Sara, De Divitiis Chiara, Nappi Anna, Napolitano Maria, Tatangelo Fabiana, Pacelli Roberto, Izzo Francesco, Vuttariello Emilia, Botti Gerardo, Scala Stefan |
| Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Molecular cancer 2018 Apr 17 (1): 81. Liu Liang, Ruiz Jimmy, O'Neill Stacey S, Grant Stefan C, Petty W Jeffrey, Yang Meng, Chen Kexin, Topaloglu Umit, Pasche Boris, Zhang W |
| Prevalence of the most common pathogenic variants in three genes for inborn errors of metabolism associated with sudden unexpected death in infancy: a population-based study in south Brazil. Genetics and molecular biology 2020 7 43 (3): 20190298. Randon Dévora N, Sperb-Ludwig Fernanda, Vianna Fernanda S L, Becker Ana P P, Vargas Carmen R, Sitta Angela, Sant'Ana Alexia N, Schwartz Ida V D, Bitencourt Fernanda H |
| High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. In vivo (Athens, Greece) 0 34 (4): 2009-2014. Santarpia Mariacarmela, Altavilla Giuseppe, Borsellino Nicolo, Girlando Andrea, Mancuso Gianfranco, Pergolizzi Stefano, Piazza Dario, Pontoriero Antonio, Valerio Maria Rosaria, Gebbia Vittor |
| Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. Journal for immunotherapy of cancer 2021 May 9 (5): . Huang Xin, He Minjun, Peng Hongyu, Tong Chongjie, Liu Zhimin, Zhang Xiaolong, Shao Yang, Zhu Dongqin, Zhang Junli, Yin Jiani C, Yang Fan, Lan Chuny |
| Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical lung cancer 2021 Mar . Kao Chester, Powers Eric, Wu Yuan, Datto Michael B, Green Michelle F, Strickler John H, Ready Neal E, Zhang Tian, Clarke Jeffrey |
| Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer. Human vaccines & immunotherapeutics 2021 Mar 1-11. Yu Yaojun, Zhang Jing, Ni Leyi, Zhu Yuesheng, Yu Hejie, Teng Yangyang, Lin Limiao, Xue Zhanxiong, Xue Xiangyang, Shen Xian, Song Haiping, Su Xiaoping, Sun Weihong, Cai Zhenzh |
| GRB10 rs1800504 Polymorphism Is Associated With the Risk of Coronary Heart Disease in Patients With Type 2 Diabetes Mellitus. Frontiers in cardiovascular medicine 2021 10 8 728976. Yang Yang, Qiu Wentao, Meng Qian, Liu Mouze, Lin Weijie, Yang Haikui, Wang Ruiqi, Dong Jiamei, Yuan Ningning, Zhou Zhiling, He Fazho |
| Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. Translational lung cancer research 2020 Dec 9 (6): 2367-2379. Xu Yanjun, Li Hui, Huang Zhiyu, Chen Kaiyan, Yu Xiaoqing, Sheng Jiamin, Zhang Han-Han, Fan Y |
| PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cancers 2021 Sep 13 (18): . Cho Yoon Ah, Lee Hyunwoo, Kim Deok Geun, Kim Hyunjin, Ha Sang Yun, Choi Yoon-La, Jang Kee-Taek, Kim Kyoung-M |
| Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers. Journal of the European Academy of Dermatology and Venereology : JEADV 2022 9 37 (2): 284-292. Pissa Maria, Lapins Jan, Sköldmark Christina, Helgadottir Hild |
| Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 2022 Sep . Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J |
| Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jul . Chiang Nai-Jung, Tan Kien Thiam, Bai Li-Yuan, Hsiao Chin-Fu, Huang Chung-Yu, Hung Yi-Ping, Huang Chien-Jui, Chen San-Chi, Shan Yan-Shen, Chao Yee, Huang Yi-Hsiang, Lee I-Cheng, Lee Pei-Chang, Su Yung-Yeh, Chen Shu-Jen, Yeh Chun-Nan, Chen Li-Tzong, Chen Ming-Hua |
| A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 7 28 (19): 4240-4247. Jung Hyun Ae, Park Keon-Uk, Cho Sanghee, Lim Jinyeong, Lee Keun-Wook, Hong Min Hee, Yun Tak, An Ho Jung, Park Woong-Yang, Pereira Sergio, Ock Chan-Young, Keam Bhums |
| Prognostic significance of PD-L1 expression and CD8 TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: a retrospective study. Journal of thoracic disease 2022 7 14 (6): 2224-2234. Cheng Xiaomin, Wang Lei, Zhang Zhem |
| Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer. Gland surgery 2022 3 11 (2): 319-329. Lan Jing, Zhou Ye-Hui, Zhang Min-Xia, Chen Dong-Qin, Wu Meng-Yao, Yu Zheng-Yu |
| PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival. Cancers 2022 3 14 (5): . Cochicho Daniela, Esteves Susana, Rito Miguel, Silva Fernanda, Martins Luís, Montalvão Pedro, Cunha Mário, Magalhães Miguel, Gil da Costa Rui M, Felix A |
| Using genotype to assist clinical surveillance: a retrospective study of Chinese familial adenomatous polyposis patients. American journal of cancer research 2022 10 12 (9): 4254-4266. Ge Sai, Cheng Duo, Zhang Xuhui, Xu Ting, Wang Zhenghang, Dong Fengxiao, Su Lan, Song Jinlei, Wang Jia, Li Jian, Shen Lin, Wang Xiche |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
| PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2023 7 35 (3): 316-330. Gangjian Wang, Xin Ji, Haojie Wang, Xiaohuan Tang, Xiaofang Xing, Jiafu |
| Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. European journal of cancer (Oxford, England : 1990) 2023 4 187 15-24. Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietranton |
| Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung cancer (Amsterdam, Netherlands) 2023 1 176 103-111. Tamiya Yutaro, Matsumoto Shingo, Zenke Yoshitaka, Yoh Kiyotaka, Ikeda Takaya, Shibata Yuji, Kato Terufumi, Nishino Kazumi, Nakamura Atsushi, Furuya Naoki, Miyamoto Shingo, Kuyama Shoichi, Nomura Shogo, Ikeno Takashi, Udagawa Hibiki, Sugiyama Eri, Nosaki Kaname, Izumi Hiroki, Sakai Tetsuya, Hashimoto Naozumi, Goto Koic |
| Clinical and molecular features of early onset pancreatic adenocarcinoma. International journal of cancer 2024 8 . Maxime Rémond, Cristina Smolenschi, Anthony Tarabay, Maximiliano Gelli, Elena Fernandez-de-Sevilla, Ali Mouawia, Simona Cosconea, Lambros Tselikas, Remy Barbe, Alina Fuerea, Mohamed A Bani, Marc Deloger, Benjamin Besse, Thomas Pudlarz, Marine Valéry, Valérie Boige, Antoine Hollebecque, Michel Ducreux, Alice Boilè |
| Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials. Therapeutic drug monitoring 2024 6 . Wei Ren, Yingying Fang, Yujing He, Yifeng Ren, Minfang Wang, Anyi Xu, Jiale Ruan, Qinghua T |
| The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO open 2024 5 9 (5): 102964. L Buisseret, Y Bareche, D Venet, E Girard, A Gombos, P Emonts, S Majjaj, G Rouas, M Serra, V Debien, E Agostinetto, S Garaud, K Willard-Gallo, D Larsimont, J Stagg, F Rothé, C Sotiri |
| Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2024 5 . M Ambrosini, B Rousseau, P Manca, O Artz, A Marabelle, T André, G Maddalena, G Mazzoli, R Intini, R Cohen, A Cercek, N H Segal, L Saltz, A M Varghese, R Yaeger, M Nusrat, Z Goldberg, G Y Ku, I El Dika, O Margalit, A Grinshpun, P Kasi, R Schilsky, A Lutfi, E Shacham-Shmueli, M Khan Afghan, L Weiss, C B Westphalen, V Conca, B Decker, G Randon, E Elez, M Fakih, A B Schrock, C Cremolini, P Jayachandran, M J Overman, S Lonardi, F Pietranton |
- Page last reviewed:Feb 1, 2024
- Content source: